OBJECTIVES: Biochemical markers reflecting the degradation of the type II collagen helical (Helix-II) and type II collagen C telopeptides (CTX-II) have been developed. AIM: To investigate the association of rapidly destructive hip osteoarthritis with urinary Helix-II and urinary CTX-II. PATIENTS AND METHODS: 12 patients (mean age 70 years) meeting the criteria for rapidly destructive hip osteoarthritis and 28 patients with slowly progressive hip osteoarthritis (mean age 63 years) defined as <0.20 mm joint space loss/year were included in a case-control study. In each patient, urinary Helix-II and CTX-II were measured at the end of the follow-up period, with retrospective evaluation of x rays. RESULTS: Helix-II levels were 41% (p = 0.002) higher in the 40 patients with hip osteoarthritis than in 75 healthy controls. Increased Helix-II levels were associated with decreased minimum joint space width of the hip (r = -0.57, p = 0.001). Mean urinary Helix-II levels were 71% higher in rapidly destructive than in slowly progressive disease (mean (standard deviation (SD)) ng/mmol Cr: 396 (160) v 232 (118) ng/mmol; p = 0.002). When levels of Helix-II and CTX-II in the highest tertile were both included in a multivariate logistic regression model, high Helix-II level (OR; (95% CI) 5.73 (1.01 to 32.8)) after adjustment for age and body mass index and high CTX-II level (6.67 (1.14 to 39.0)) were, independently of each other, associated with a rapidly destructive disease. CONCLUSION: Increased urinary Helix-II levels are associated with rapidly destructive hip osteoarthritis, independently of urinary CTX-II. Measurement of Helix-II, alone or in combination with CTX-II, could be useful for the clinical investigation of patients with hip osteoarthritis.
OBJECTIVES: Biochemical markers reflecting the degradation of the type II collagen helical (Helix-II) and type II collagen C telopeptides (CTX-II) have been developed. AIM: To investigate the association of rapidly destructive hip osteoarthritis with urinary Helix-II and urinary CTX-II. PATIENTS AND METHODS: 12 patients (mean age 70 years) meeting the criteria for rapidly destructive hip osteoarthritis and 28 patients with slowly progressive hip osteoarthritis (mean age 63 years) defined as <0.20 mm joint space loss/year were included in a case-control study. In each patient, urinary Helix-II and CTX-II were measured at the end of the follow-up period, with retrospective evaluation of x rays. RESULTS: Helix-II levels were 41% (p = 0.002) higher in the 40 patients with hip osteoarthritis than in 75 healthy controls. Increased Helix-II levels were associated with decreased minimum joint space width of the hip (r = -0.57, p = 0.001). Mean urinary Helix-II levels were 71% higher in rapidly destructive than in slowly progressive disease (mean (standard deviation (SD)) ng/mmol Cr: 396 (160) v 232 (118) ng/mmol; p = 0.002). When levels of Helix-II and CTX-II in the highest tertile were both included in a multivariate logistic regression model, high Helix-II level (OR; (95% CI) 5.73 (1.01 to 32.8)) after adjustment for age and body mass index and high CTX-II level (6.67 (1.14 to 39.0)) were, independently of each other, associated with a rapidly destructive disease. CONCLUSION: Increased urinary Helix-II levels are associated with rapidly destructive hip osteoarthritis, independently of urinary CTX-II. Measurement of Helix-II, alone or in combination with CTX-II, could be useful for the clinical investigation of patients with hip osteoarthritis.
Authors: J T Downs; C L Lane; N B Nestor; T J McLellan; M A Kelly; G A Karam; P S Mezes; J P Pelletier; I G Otterness Journal: J Immunol Methods Date: 2001-01-01 Impact factor: 2.303
Authors: Patrick Garnero; Xavier Ayral; Jean-Charles Rousseau; S Christgau; Linda J Sandell; Maxime Dougados; Pierre D Delmas Journal: Arthritis Rheum Date: 2002-10
Authors: Patrick Garnero; Robert Landewé; Maarten Boers; Arco Verhoeven; Sjef Van Der Linden; Stephan Christgau; Désirée Van Der Heijde; Annelies Boonen; Piet Geusens Journal: Arthritis Rheum Date: 2002-11
Authors: N Charni-Ben Tabassi; S Desmarais; A-C Bay-Jensen; J M Delaissé; M D Percival; P Garnero Journal: Osteoarthritis Cartilage Date: 2008-04-09 Impact factor: 6.576
Authors: Jeffrey J Nepple; Kayla M Thomason; Tonya W An; Marcie Harris-Hayes; John C Clohisy Journal: Clin Orthop Relat Res Date: 2015-05 Impact factor: 4.176
Authors: Steven K Leckie; Bernard P Bechara; Robert A Hartman; Gwendolyn A Sowa; Barrett I Woods; Joao P Coelho; William T Witt; Qing D Dong; Brent W Bowman; Kevin M Bell; Nam V Vo; Bing Wang; James D Kang Journal: Spine J Date: 2011-10-22 Impact factor: 4.166
Authors: Erik B Dam; Marco Loog; Claus Christiansen; Inger Byrjalsen; Jenny Folkesson; Mads Nielsen; Arish A Qazi; Paola C Pettersen; Patrick Garnero; Morten A Karsdal Journal: Arthritis Res Ther Date: 2009-07-24 Impact factor: 5.156
Authors: Virginia Byers Kraus; Jamie E Collins; David Hargrove; Elena Losina; Michael Nevitt; Jeffrey N Katz; Susanne X Wang; Linda J Sandell; Steven C Hoffmann; David J Hunter Journal: Ann Rheum Dis Date: 2016-06-13 Impact factor: 19.103
Authors: Zhenhong Ni; Siru Zhou; Song Li; Liang Kuang; Hangang Chen; Xiaoqing Luo; Junjie Ouyang; Mei He; Xiaolan Du; Lin Chen Journal: Bone Res Date: 2020-06-19 Impact factor: 13.567